Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib

A 53-year old white, female former-smoker (15 pack-years) was diagnosed with non–small-cell lung cancer (NSCLC) of the middle lobe in April 2016. Histopathologic evaluation revealed an adenocarcinoma with a common sensitizing (Exon 19 deletion) epidermal growth factor receptor (EGFR) mutation (c.2235_2249delGGAATTAAGAGAAGC, p.Glu746_Ala750del). The initial tumor stage was cT2 cN3 cM0. The patient presented herself in good general condition (performance status [PS], 0) and with a history of Hashimoto thyroiditis and no further comorbidity.